Articles On Patrys (ASX:PAB)
| Title | Source | Codes | Date |
|---|---|---|---|
|
Animal data shows potential for Patrys’ PAT-DX1 drug to help radiation fight aggressive brain tumours
Therapeutic antibody developer Patrys (ASX: PAB) has revealed new pre-clinical animal data that points to the potential for its lead candidate drug PAT-DX1 to improve survival rates for patients with highly aggressive forms of brain tumours... |
SmallCaps | PAB | 5 years ago |
|
Health: Patrys takes another step towards clinical trials for cancer-fighting tech
Biotech company Patrys Limited (ASX:PAB) shares got a bump this morning, after some more positive animal tests for its PAT-DX1 cancer treatment. A completed study at Yale School of Medicine shows PAT-DX1 has the potential to improve radiati... |
Stockhead | PAB | 5 years ago |
|
Top 10 at 10: These ASX stocks are climbing high this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel... |
Stockhead | PAB | 5 years ago |
|
Dr Boreham’s Crucible: ‘Robust’ biotech and Kerry Stokes as a backer, so what’s holding down Patrys’ share price?
The cancer drug developer adheres to that perverse law of diminishing returns that states: “The more a biotech company progresses down its chosen therapeutic path, the less it should be valued.” In Patrys’ (ASX:PAB) case, the stock has lost... |
Stockhead | PAB | 5 years ago |